We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Seeks Additional Trial for Acadia’s Nuplazid Alzheimer’s sNDA
FDA Seeks Additional Trial for Acadia’s Nuplazid Alzheimer’s sNDA
In a continuing saga of disapprovals, the FDA issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals on its supplemental New Drug Application (sNDA) to expand the use of its Parkinson’s psychosis drug Nuplazid (pimavanserin) for treatment of Alzheimer’s disease psychosis (ADP).